Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
Trump Says Anthropic No Longer Seen as National Security Threat 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
BRANFORD, Conn., Jan. 11, 2016 (GLOBE NEWSWIRE) -- BioXcel Corporation, a global leader in developing cloud-based big data platforms and transformative patient treatments, today announced a strategic big data collaboration with Centrexion Therapeutics to develop a portfolio of clinical pain therapeutic assets.
Centrexion is focused on developing and commercializing new treatments for chronic pain with better efficacy and safety than current treatment paradigms. Through this collaboration, Centrexion will leverage BioXcel's first-in-class Big Data Innovation Lab (BDI-Lab) to generate optimal therapeutic value at the intersection of pain biology and differentiated products with a higher probability of clinical and commercial success. This complex association of drugs and disease will involve big data analytics to decipher network pharmacology combined with deep expertise to generate product development blueprints for transformational pain therapeutics.
“This partnership allows us to combine our distinctive translational medicine approach with BioXcel’s world-class big data platform and discovery engine to develop new non-opioid therapies to treat chronic pain. We are pleased to partner with BioXcel on this important initiative and to deliver new and innovative solutions to patients in need,” said Kerrie Brady Chief Business Officer, Centrexion Therapeutics.
"We are excited to partner with Centrexion to support the development of innovative treatments for chronic pain," stated Frank D.Yocca Senior Vice President, CNS Research & Development, BioXcel Corporation. “Our Big Data Innovation Lab has diverse application in CNS diseases and across multiple therapeutic areas, as evident from our partnerships with Takeda, Alexion, Pronutria and many others. We expect that the combination of our respective capabilities will drive significant improvements in the speed and efficiency of Centrexion’s drug development initiatives.”
Under the terms of the agreement, BioXcel will receive an upfront payment, as well as development and commercial milestone payments. Financial details are not disclosed.
About BioXcel
BioXcel is a global leader in providing cloud-based Pharma big data solutions for discovering novel products and performance benchmarking of pipeline innovation and marketed products in all major therapeutic areas. Our first in class Big Data Innovation Lab is focused on the development of transformative patient treatments for strategic portfolio growth and leverages; PharmGPS® - a live analytics platform; an Integrated Center of Xcellence housing multidisciplinary scientific, commercial and medical teams; and a drug development team that offers deep domain expertise. Committed to innovation, product excellence and partner success, BioXcel's global collaborations span the biopharmaceutical ecosystem. We are headquartered in Branford, CT, USA with operations in Asia.
Contact: BioXcel Corporation Anita Ganjoo Corporate Communications Email: [email protected] Tel: 203 957 2487
